Abstract
We compared the effects of ezetimibe/rosuvastatin 10/5 mg versus rosuvastatin 20 mg on carotid atherosclerotic plaque inflammation measured by 18FDG PET/CT. Fifty patients with acute coronary syndrome (ACS) were randomly assigned to the ezetimibe/rosuvastatin 10/5 mg and rosuvastatin 20 mg groups. The primary outcome was the percent change in the target-to-background ratio (TBR) of the index vessel in the most diseased segment (MDS), as assessed by 18FDG PET/CT at baseline and at 6 months. Forty-eight patients completed follow-up PET/CT. MDS TBR was − 6.2 ± 13.9% for patients in the ezetimibe/rosuvastatin group and − 10.8 ± 17.7% for those in the rosuvastatin group (difference, 4.6 percentage points; upper limitation of one-sided confidence interval = 13.8; p = 0.60 for noninferiority). In conclusion, combination therapy with ezetimibe 10 mg and rosuvastatin 5 mg compared with rosuvastatin 20 mg did not meet the criterion for non-inferiority for primary outcome, and the present study was not conclusive on whether the former was non-inferior to the latter. [Figure not available: see fulltext.].
Original language | English |
---|---|
Pages (from-to) | 900-907 |
Number of pages | 8 |
Journal | Journal of Cardiovascular Translational Research |
Volume | 13 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2020 Dec |
Externally published | Yes |
Keywords
- Ezetimibe
- Plaque inflammation
- Positron emission tomography
- Statin
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmaceutical Science
- Cardiology and Cardiovascular Medicine
- Genetics(clinical)